...
首页> 外文期刊>Clinical and experimental ophthalmology >Long-term follow up of autologous serum treatment for recurrent corneal erosions.
【24h】

Long-term follow up of autologous serum treatment for recurrent corneal erosions.

机译:自体血清治疗对复发性角膜糜烂的长期随访。

获取原文
获取原文并翻译 | 示例

摘要

PURPOSE: The aim of the study was to evaluate long-term results of autologous serum treatment for recurrent corneal erosions. METHODS: In this prospective single-centre study, 33 eyes of 33 patients (21 male and 12 female) were treated with autologous serum eye drops for recurrent corneal erosions. Mean age of the patients was 49.3 +/- 9.8 standard deviation (range 24-73) years. All subjects had failed to respond to other treatments. Autologous serum drops were administered for a 6-month period: six times daily for the first 3 months and four times daily for the remaining 3 months. Detailed informed consent was obtained from the entire patient group before the study. RESULTS: The mean follow-up period was 30 +/- 6.3 standard deviation (range 12-48) months. None of the patients experienced a recurrence while under treatment. Twenty-eight patients (85%) had complete healing of erosions with no relapses of the disease over the whole follow-up period. Five patients (15%) presented a single recurrence 3-12 months after the end of the treatment. No sight-threatening complications were reported over the follow up. There was no statistically significant difference in the best spectacle-corrected visual acuity values (t(stat) = 2.1, F = 0.096, degree of freedom = 40,166, P < 0.41) or in the intraocular pressure measurements (P < 0.38) between the pre- and post-treatment patient groups. CONCLUSIONS: Autologous serum drops proved to be a safe and efficient treatment modality for patients with recurrent corneal erosion syndrome as observed through a long-term follow up.
机译:目的:本研究的目的是评估自体血清治疗复发性角膜糜烂的长期结果。方法:在这项前瞻性单中心研究中,对33例患者中的33眼(男21例,女12例)进行了自体血清滴眼液治疗,以防止复发性角膜糜烂。患者的平均年龄为49.3 +/- 9.8标准偏差(范围24-73)年。所有受试者均未对其他治疗产生反应。自体血清滴剂的给药期为6个月:头3个月每天6次,其余3个月每天4次。研究前从整个患者组获得了详细的知情同意书。结果:平均随访期为30 +/- 6.3标准差(范围12-48)个月。所有患者均未接受治疗。 28名患者(85%)的糜烂完全愈合,在整个随访期间均未复发。五名患者(15%)在治疗结束后3-12个月出现一次复发。随访中未见威胁视力的并发症。最佳眼镜矫正视力值(t(stat)= 2.1,F = 0.096,自由度= 40,166,P <0.41)或眼压测量值(P <0.38)之间在统计学上无显着差异。治疗前和治疗后的患者组。结论:经长期随访观察,自体血清滴剂被证明是复发性角膜侵蚀综合征患者的一种安全有效的治疗方式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号